Pathfinder Cell Therapy, Inc. (PFND)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2014 | 1.11 Million USD | -30.75% |
| 2013 | 1.61 Million USD | -23.92% |
| 2012 | 2.12 Million USD | -42.05% |
| 2011 | 3.66 Million USD | 33.22% |
| 2010 | 2.75 Million USD | -36.26% |
| 2009 | 4.31 Million USD | -7.24% |
| 2008 | 4.65 Million USD | -14.62% |
| 2007 | 5.45 Million USD | 17.05% |
| 2006 | 4.65 Million USD | 89.19% |
| 2005 | 2.46 Million USD | 3.49% |
| 2004 | 2.37 Million USD | 17.84% |
| 2003 | 2.01 Million USD | 57.17% |
| 2002 | 1.28 Million USD | 15.68% |
| 2001 | 1.11 Million USD | -0.8% |
| 2000 | 1.11 Million USD | -61.93% |
| 1999 | 2.93 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2015 Q2 | 144 Thousand USD | -29.41% |
| 2015 Q1 | 204 Thousand USD | -6.42% |
| 2015 Q3 | 209 Thousand USD | 45.14% |
| 2014 Q3 | 213 Thousand USD | -19.62% |
| 2014 FY | 1.11 Million USD | -30.75% |
| 2014 Q2 | 265 Thousand USD | -37.35% |
| 2014 Q4 | 218 Thousand USD | 2.35% |
| 2014 Q1 | 423 Thousand USD | 7.09% |
| 2013 Q3 | 324 Thousand USD | -4.99% |
| 2013 Q4 | 395 Thousand USD | 21.91% |
| 2013 Q1 | 556 Thousand USD | 12.1% |
| 2013 Q2 | 341 Thousand USD | -38.67% |
| 2013 FY | 1.61 Million USD | -23.92% |
| 2012 Q2 | 628 Thousand USD | 10.56% |
| 2012 Q4 | 496 Thousand USD | 14.81% |
| 2012 FY | 2.12 Million USD | -42.05% |
| 2012 Q1 | 568 Thousand USD | 1.07% |
| 2012 Q3 | 432 Thousand USD | -31.21% |
| 2011 Q3 | 2.02 Million USD | 482.71% |
| 2011 Q2 | 347 Thousand USD | -21.67% |
| 2011 Q1 | 443 Thousand USD | -7.71% |
| 2011 FY | 3.66 Million USD | 33.22% |
| 2011 Q4 | 562 Thousand USD | -72.21% |
| 2010 Q3 | 642 Thousand USD | -8.55% |
| 2010 Q1 | 926 Thousand USD | -0.22% |
| 2010 Q2 | 702 Thousand USD | -24.19% |
| 2010 Q4 | 480 Thousand USD | -25.23% |
| 2010 FY | 2.75 Million USD | -36.26% |
| 2009 Q1 | 1.05 Million USD | 0.0% |
| 2009 Q3 | 1.1 Million USD | -9.93% |
| 2009 FY | 4.31 Million USD | -7.24% |
| 2009 Q4 | 928 Thousand USD | -16.17% |
| 2009 Q2 | 1.22 Million USD | 16.83% |
| 2008 Q1 | 1.51 Million USD | 34.61% |
| 2008 Q4 | 1.05 Million USD | -1.5% |
| 2008 FY | 4.65 Million USD | -14.62% |
| 2008 Q3 | 1.06 Million USD | 5.01% |
| 2008 Q2 | 1.01 Million USD | -32.96% |
| 2007 Q4 | 1.12 Million USD | -15.71% |
| 2007 FY | 5.45 Million USD | 17.05% |
| 2007 Q1 | 1.25 Million USD | 23.74% |
| 2007 Q2 | 1.73 Million USD | 38.85% |
| 2007 Q3 | 1.33 Million USD | -23.03% |
| 2006 Q3 | 843 Thousand USD | -54.26% |
| 2006 Q4 | 1.01 Million USD | 19.93% |
| 2006 FY | 4.65 Million USD | 89.19% |
| 2006 Q2 | 1.84 Million USD | 92.18% |
| 2006 Q1 | 959 Thousand USD | 55.43% |
| 2005 Q2 | 641 Thousand USD | 23.51% |
| 2005 Q3 | 684 Thousand USD | 6.71% |
| 2005 Q4 | 617 Thousand USD | -9.8% |
| 2005 Q1 | 519 Thousand USD | -3.71% |
| 2005 FY | 2.46 Million USD | 3.49% |
| 2004 Q4 | 539 Thousand USD | 12.53% |
| 2004 Q2 | 598 Thousand USD | -20.69% |
| 2004 Q1 | 754 Thousand USD | 96.35% |
| 2004 FY | 2.37 Million USD | 17.84% |
| 2004 Q3 | 479 Thousand USD | -19.9% |
| 2003 Q1 | 585 Thousand USD | -12.56% |
| 2003 FY | 2.01 Million USD | 57.17% |
| 2003 Q4 | 384 Thousand USD | 33.33% |
| 2003 Q3 | 288 Thousand USD | -61.75% |
| 2003 Q2 | 753 Thousand USD | 28.72% |
| 2002 Q1 | 232 Thousand USD | 4.04% |
| 2002 FY | 1.28 Million USD | 15.68% |
| 2002 Q2 | 195 Thousand USD | -15.95% |
| 2002 Q4 | 669 Thousand USD | 255.85% |
| 2002 Q3 | 188 Thousand USD | -3.59% |
| 2001 Q4 | 223 Thousand USD | 74.22% |
| 2001 Q3 | 128 Thousand USD | -68.47% |
| 2001 Q2 | 406 Thousand USD | 18.37% |
| 2001 Q1 | 343 Thousand USD | 31.42% |
| 2001 FY | 1.11 Million USD | -0.8% |
| 2000 Q4 | 261 Thousand USD | 59.15% |
| 2000 Q1 | 337 Thousand USD | 0.0% |
| 2000 Q3 | 164 Thousand USD | -54.19% |
| 2000 Q2 | 358 Thousand USD | 6.23% |
| 2000 FY | 1.11 Million USD | -61.93% |
| 1999 FY | 2.93 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 16.207% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 77.807% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 96.214% |
| Nascent Biotech, Inc. | 2.22 Million USD | 49.818% |
| Rebus Holdings, Inc. | 664 Thousand USD | -68.524% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 96.996% |
| Qrons Inc. | 643.67 Thousand USD | -73.845% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -187.243% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.052% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -169.328% |
| Skye Bioscience, Inc. | 13.54 Million USD | 91.74% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.711% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 77.246% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -327.546% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.693% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 61.629% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 25.494% |
| Mesoblast Limited | 5.9 Million USD | 81.04% |
| Marizyme, Inc. | 19.23 Million USD | 94.184% |
| Genus plc | 147.7 Million USD | 99.242% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 87.254% |
| Pharming Group N.V. | 225.49 Million USD | 99.504% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 45.38% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 16.589% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 86.581% |
| ContraFect Corporation | 56.88 Million USD | 98.033% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 74.618% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 24.328% |
| IMV Inc. | 37.7 Million USD | 97.033% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 59.898% |
| MultiCell Technologies, Inc. | 567.42 USD | -197108.417% |
| ONE Bio Corp. | 6.44 Million USD | 82.635% |
| Accustem Sciences Inc. | 3.74 Million USD | 70.131% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.698% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -110.353% |
| Q BioMed Inc. | 3.43 Million USD | 67.439% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 95.472% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 57.412% |
| Biomind Labs Inc. | 994.18 Thousand USD | -12.555% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.873% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 36.409% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 83.343% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 39.98% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 4576.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 93.011% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 39.022% |
| GB Sciences, Inc. | 1.42 Million USD | 21.225% |
| Alpha Cognition Inc. | 9.7 Million USD | 88.471% |
| HST Global, Inc. | 140.9 Thousand USD | -694.141% |
| CSL Limited | 3.44 Billion USD | 99.968% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 0.525% |
| Halberd Corporation | 74.84 Thousand USD | -1395.15% |
| Enzolytics Inc. | 2.17 Million USD | 48.658% |
| Agentix Corp. | 1.37 Million USD | 18.426% |
| Resverlogix Corp. | 12.71 Million USD | 91.197% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 69.348% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.927% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -7.184% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 53.471% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 29.148% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 67.136% |
| AVAX Technologies, Inc. | 7.31 Million USD | 84.693% |
| Zenith Capital Corp. | 8.94 Million USD | 87.487% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.864% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -6323.282% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 54.425% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -552.444% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 41.746% |
| Kadimastem Ltd | 2.41 Million USD | 53.571% |
| Helix BioMedix, Inc. | 1.97 Million USD | 43.257% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 89.703% |
| BioStem Technologies, Inc. | 22.97 Million USD | 95.129% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -516.58% |
| LadRx Corporation | 3.81 Million USD | 70.644% |
| Cell Source, Inc. | 4.32 Million USD | 74.129% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -21.168% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -21.168% |
| NovAccess Global Inc. | 2.46 Million USD | 54.637% |
| Affymax, Inc. | 39.38 Million USD | 97.159% |
| Itoco Inc. | 919.14 Thousand USD | -21.744% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 73.599% |
| Mobile Lads Corp. | 554.54 Thousand USD | -101.787% |
| CytoDyn Inc. | 18.05 Million USD | 93.803% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -4345.945% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -408.456% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 21.186% |
| SYBLEU INC | 160.87 Thousand USD | -595.567% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 38.392% |
| International Stem Cell Corporation | 5.27 Million USD | 78.771% |
| Bioxytran, Inc. | 3.82 Million USD | 70.708% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2025.679% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -5400.664% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 96.914% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 30.841% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -52.072% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 64.031% |
| Neutra Corp. | 243.82 Thousand USD | -358.943% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 93.59% |
| PureTech Health plc | 144.59 Million USD | 99.226% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 94.539% |
| IXICO plc | 4.7 Million USD | 76.227% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 87.28% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.05% |
| CSL Limited | 3.89 Billion USD | 99.971% |
| Cellectis S.A. | 97.32 Million USD | 98.85% |